JP2023524434A - 新規療法 - Google Patents

新規療法 Download PDF

Info

Publication number
JP2023524434A
JP2023524434A JP2022565781A JP2022565781A JP2023524434A JP 2023524434 A JP2023524434 A JP 2023524434A JP 2022565781 A JP2022565781 A JP 2022565781A JP 2022565781 A JP2022565781 A JP 2022565781A JP 2023524434 A JP2023524434 A JP 2023524434A
Authority
JP
Japan
Prior art keywords
cells
icam3
cov
sars
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524434A5 (enExample
Inventor
テレサ デイシャー、
スコット ウェイン マッケイ、
Original Assignee
エーブイエム・バイオテクノロジー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーブイエム・バイオテクノロジー・エルエルシー filed Critical エーブイエム・バイオテクノロジー・エルエルシー
Publication of JP2023524434A publication Critical patent/JP2023524434A/ja
Publication of JP2023524434A5 publication Critical patent/JP2023524434A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022565781A 2020-04-29 2021-04-28 新規療法 Pending JP2023524434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017199P 2020-04-29 2020-04-29
US63/017,199 2020-04-29
PCT/US2021/029608 WO2021222385A1 (en) 2020-04-29 2021-04-28 Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus

Publications (2)

Publication Number Publication Date
JP2023524434A true JP2023524434A (ja) 2023-06-12
JP2023524434A5 JP2023524434A5 (enExample) 2024-05-08

Family

ID=76270026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565781A Pending JP2023524434A (ja) 2020-04-29 2021-04-28 新規療法

Country Status (7)

Country Link
US (1) US20230172950A1 (enExample)
EP (1) EP4142736A1 (enExample)
JP (1) JP2023524434A (enExample)
KR (1) KR20230015927A (enExample)
CN (1) CN115666583A (enExample)
BR (1) BR112022021691A2 (enExample)
WO (1) WO2021222385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540319A (ja) * 2021-11-05 2024-10-31 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514788A (ja) * 2020-02-28 2023-04-10 エーブイエム・バイオテクノロジー・エルエルシー リンパ球集団およびそれを生産するための方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514788A (ja) * 2020-02-28 2023-04-10 エーブイエム・バイオテクノロジー・エルエルシー リンパ球集団およびそれを生産するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BELVISI M. G. ET AL., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 314, no. 2, JPN6025022309, 2005, pages 568 - 574, ISSN: 0005817586 *
JUAN M. ET AL., ALLERGY, vol. 54, JPN6025022310, 1999, pages 1293 - 1298, ISSN: 0005608986 *
MATSUYAMA S. ET AL.: "The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15.", BIORXIV, JPN6025022308, 12 March 2020 (2020-03-12), ISSN: 0005817585 *
XIANG Z. ET AL., INT. J. BIOL. SCI., vol. 16, JPN6025022311, 27 June 2020 (2020-06-27), pages 2382 - 2391, ISSN: 0005608987 *

Also Published As

Publication number Publication date
BR112022021691A2 (pt) 2022-12-20
CN115666583A (zh) 2023-01-31
KR20230015927A (ko) 2023-01-31
WO2021222385A1 (en) 2021-11-04
US20230172950A1 (en) 2023-06-08
EP4142736A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
Zhou et al. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Qu et al. BCG vaccination strategies against tuberculosis: updates and perspectives
Luo et al. Precisely regulating M2 subtype macrophages for renal fibrosis resolution
US11419879B2 (en) Methods for treating and preventing viral infections
Johnson et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis
Saxena et al. Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: a randomized double-blinded placebo controlled trial
Bajwa et al. Immune mechanisms and novel pharmacological therapies of acute kidney injury
JP2023522249A (ja) コロナウイルスワクチン
Armitage Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
Zhu et al. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
JP2023524434A (ja) 新規療法
Morrow et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1
Mehraj et al. Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy
SA519410007B1 (ar) مركبات ببتيد وطرق لمعالجة السكر
Choi et al. Indispensable role of CX3CR1+ dendritic cells in regulation of virus-induced neuroinflammation through rapid development of antiviral immunity in peripheral lymphoid tissues
Mitchell et al. Exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) renders influenza virus-specific CD8+ T cells hyporesponsive to antigen
Xu et al. Hemin protects against Zika virus infection by disrupting virus-endosome fusion
Park et al. Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage
Thomas et al. Antigen presentation by nonhemopoietic cells amplifies clonal expansion of effector CD8 T cells in a pathogen-specific manner
AU2017224499A1 (en) Pharmaceutical composition for preventing or treating regulatory T cell-mediated diseases
Beauseéjour et al. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane
Quakkelaar et al. IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation
US20240293456A1 (en) Combinations of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of treating cancer using the same
Ling et al. In situ activation of antigen-specific CD8+ T cells in the presence of antigen in organotypic brain slices
Jiang et al. Optimized multi-epitope neoantigen human cytomegalovirus vaccine based on adenovirus vectors elicits potent antiviral immunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317